Technical Analysis for NLNK - NewLink Genetics Corporation

Grade Last Price % Change Price Change
grade F 1.51 0.00% 0.00
NLNK closed down 0.66 percent on Thursday, January 17, 2019, on 64 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NLNK trend table...

Date Alert Name Type % Chg
Jan 17 20 DMA Resistance Bearish 0.00%
Jan 16 20 DMA Resistance Bearish -0.66%
Jan 16 180 Bearish Setup Bearish Swing Setup -0.66%
Jan 15 20 DMA Resistance Bearish -1.95%
Jan 15 Hammer Candlestick Bullish -1.95%
Jan 14 Down 3 Days in a Row Weakness -1.31%
Jan 14 Down 4 Days in a Row Weakness -1.31%
Jan 11 NR7 Range Contraction -2.58%
Jan 11 Down 3 Days in a Row Weakness -2.58%
Jan 10 20 DMA Resistance Bearish -3.21%

Older signals for NLNK ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
NewLink Genetics Corporation, a biopharmaceutical company, through its subsidiary, BioProtection Systems Corporation, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance cancer treatment options for patients and physicians. Its portfolio includes biologic and small-molecule immunotherapy product candidates based on proprietary HyperAcute immunotherapy technology for the treatment of various oncology indications. The company's lead product candidate, HyperAcute Pancreas cancer immunotherapy, is being studied in two Phase III clinical trials in surgically-resected pancreatic cancer patients. It is also developing HyperAcute Lung, which is being studied in a multi-center randomized, controlled Phase IIB/III clinical trials for non-small cell lung cancer; HyperAcute Melanoma that is in Phase II clinical trials for the treatment of melanoma; and a HyperAcute Renal cell cancer immunotherapy, as well as HyperAcute prostate and HyperAcute breast product candidates. In addition, the company is developing Indoximod, a small-molecule, orally bioavailable product candidate, which is being evaluated for the treatment of metastatic solid tumors in two Phase IB/II clinical trials; Provenge Indoximod that is in Phase II clinical trials for the treatment of prostate cancer; Docetaxel Indoximod, which is in Phase II clinical trials for the treatment of metastatic breast cancer; HyperAcute immunotherapy plus Indoximod that is in Phase IIB clinical trials; and NLG-919 IDO Pathway Inhibitor Candidate, which is in Phase I clinical trials for the treatment of metastatic solid tumors. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Is NLNK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.14
52 Week Low 1.28
Average Volume 374,653
200-Day Moving Average 3.3325
50-Day Moving Average 1.7592
20-Day Moving Average 1.5365
10-Day Moving Average 1.557
Average True Range 0.1092
ADX 13.68
+DI 15.9122
-DI 20.2817
Chandelier Exit (Long, 3 ATRs ) 1.5024
Chandelier Exit (Short, 3 ATRs ) 1.6076
Upper Bollinger Band 1.6996
Lower Bollinger Band 1.3734
Percent B (%b) 0.42
BandWidth 21.230068
MACD Line -0.0623
MACD Signal Line -0.0749
MACD Histogram 0.0125
Fundamentals Value
Market Cap 44.43 Million
Num Shares 29.4 Million
EPS -2.29
Price-to-Earnings (P/E) Ratio -0.66
Price-to-Sales 6.79
Price-to-Book 2.71
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.63
Resistance 3 (R3) 1.63 1.60 1.61
Resistance 2 (R2) 1.60 1.57 1.60 1.60
Resistance 1 (R1) 1.55 1.55 1.54 1.55 1.60
Pivot Point 1.52 1.52 1.51 1.52 1.52
Support 1 (S1) 1.47 1.49 1.46 1.47 1.42
Support 2 (S2) 1.44 1.47 1.44 1.42
Support 3 (S3) 1.39 1.44 1.41
Support 4 (S4) 1.39